spacer
home > ebr > summer 2017 > strategic advantage
PUBLICATIONS
European Biopharmaceutical Review

Strategic Advantage

Pharmacovigilance (PV) is beginning to touch more aspects of life sciences organisations in the form of additional functions as well as international operations, including affiliates. Overcoming silos and establishing closer collaboration between PV and quality operations is a growing priority and, as circumstances evolve, responsibility for the monitoring of safety and associated systems will have to be shared by an increasingly diverse range of stakeholders.

Quality Rules


One thing the life sciences industry cannot escape is a heightened emphasis on quality as inspections increase. Although this presents certain obstacles, it also prompts companies to put better systems and processes in place – senior management now understands the importance of PV and are beginning to allocate more resources to it.

The conceivable downside is that too much attention on compliance could detract from the real motivation underlying all of this which is, of course, to improve patient safety and public confidence. Two ways of keeping things in clear focus are to get teams working together more readily and to take shared responsibility for making improvements.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Cheryl Key, MBBS, MFPM, is Head of Practice PV Platform Services and Principal Medic at ProductLife Group, with final responsibility for all projects, programmes and engagements in the platform, as well as for day-to-day management of the platform team. She has a medical degree from Charing Cross and Westminster Medical School, UK, a diploma in pharmaceutical medicine, membership of the Royal College of General Practitioners and membership of the Faculty of Pharmaceutical Medicine. Cheryl is also on the Specialist Register at the General Medical Council for Pharmaceutical Medicine and a member of the board of the Faculty of Pharmaceutical Medicine.
spacer
Cheryl Key
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

New awareness campaign aims to help organisations prepare for GS1


More info >>

White Papers

Value-Added Processing and Quality By Design Principles Help Meet High-Quality Demands

West Pharmaceutical Services, Inc.

The current pharmaceutical market has faced a variety of challenges, including increasing expectations for quality from end-users and regulatory agencies driven by concern for patient safety. While pharmaceutical companies are working to assure that new quality and compliance paradigms are met, a balance must be achieved between the reality of managing costs in an effort to provide a product that meets the requirements of payers along with facilitating profitability in order to continue adequate business reinvestment.
More info >>

 
Industry Events

7th annual Orphan Drugs and Rare Diseases UK

18-19 October 2017, Holiday Inn Kensington Forum, London

SMi Group is thrilled to present the 7th annual Orphan Drugs and Rare Diseases conference, taking place on 18th & 19th October 2017 in Central London, UK. This year’s theme will be focused towards discussing strategies for patient engagement, market access and gene therapies to enhance rare diseases and orphan drug research.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement